Qubing Sun

Cancer Research Institute, New York City, New York, United States

Are you Qubing Sun?

Claim your profile

Publications (4)5.5 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: Low antigenicity or development of tolerance is believed to be a major contributor to the escape of malignant tumors from immune surveillance of the host. However, anti-tumor responses can be elicited by concomitant immunization of poorly antigenic tumor cells with homologous xenogeneic proteins as 'altered self' proteins. In our study, anti-tumor, but not anti-xenogeneic antigen, immune responses were generated after transduction of the gene coding for a G-protein coupled human formyl peptide receptor like-1 (FPRL1) into a mouse C26 colon cancer cell line. C26 cells transfected with FPRL1 gene exhibited markedly reduced tumorigenicity in syngeneic mice, in association with the appearance of high levels of antibody activity reacting with both FPRL1 containing and wild type C26 cells. The anti-tumor responses required the participation of CD4+ T lymphocytes, since no tumor rejection was observed in nude mice or in syngeneic mice depleted of CD4+ T cells. Furthermore, mice primed with FPRL1 transfected C26 cells were resistant to subsequent challenge by wild type C26 cells. These results indicate that the presence of human FPRL1 is capable of triggering specific anti-tumor host immune responses against poorly antigenic mouse tumor cells.
    International Immunopharmacology 07/2005; 5(6):971-80. · 2.42 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Two anti-idiotypic monoclonal antibodies (Ab2), designated 2H4 and 5D3, against two antitumor antibodies Ab1 (FC2 and HNL5) that recognize nasopharyngeal carcinoma (NPC) associated antigen were generated. They could substitute NPC antigen to induce humoral and cellular immune response against NPC cells in syngeneic mice. Nineteen patients with NPC at stage IV were chosen for active immunotherapy. They were treated with aluminum hydroxide-precipitated Ab2 2H4 or 5D3 accompanying radiotherapy. None of the immunization of anti-idiotypic monoclonal antibody (mAb) was associated with toxicity or allergies reactions. Nine patients with radiotherapy alone served as control. Both anti-anti-idiotypic antibodies (Ab3) and anti-NPC antibodies (Ab1') were increased and human anti-mouse Ig antibodies (HAMA) occurred in nineteen patients of the experimental group; whereas the levels of Ab1' did not rise in the control group. Serum IL-2, IFN-gamma, and TNF-alpha levels were increased in most patients in the experimental group, while in the control group, there were no differences of Ab1' and cytokine level between pretherapy and posttherapy. In addition, IL-2 mRNA expression in peripheral blood mononuclear cells (PBMC) of NPC patients was closely related to serum IL-2 (r = +0.8829) by in situ hybridization. Therefore, mouse anti-idiotypic antibodies 2H4 and 5D3 are safe for active immunotherapy and might enhance humoral and/or cellular immunity of NPC patients receiving radiotherapy.
    Cancer Biotherapy and Radiopharmaceuticals 01/2003; 17(6):673-9. · 1.74 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To investigate the effect of active immunotherapy with anti-idiotypic vaccine in patients with nasopharyngeal carcinoma (NPC). Anti-idiotypic antibodies (2H4/5D3) bearing the internal image of the NPC antigen were used in active immunotherapy in NPC patients receiving radiotherapy. Antibodies and cytokine levels in patient sera were determined using ELISA before and after active immunotherapy. IL-2 mRNA expression in the peripheral blood mononuclear cells (PBMC) was measured by in situ hybridization. Nineteen patients with NPC at stage IV were treated with alum-precipitated 2H4 or 5D3. Neither hypersensitivity nor adverse side effects were observed. The levels of anti-anti-idiotypic antibodies (Ab3) and anti-NPC antibodies (Ab1') were increased. Human anti-mouse antibodies (HAMA) were seen in 19 patients of the experimental group; the levels of Ab1' did not increase in the control group. Serum IL-2, IFN-gamma and TNF-alpha levels were increased in most patients in the experimental group, while no differences were observed in Ab1' and cytokine levels between pre- and post-therapy in the control group. In addition, IL-2 mRNA expression in PBMCs from NPC patients was closely related to serum IL-2 (r = + 0.8829) levels by in situ hybridization. Anti-idiotype vaccine is safe for clinical active immunotherapy. Anti-idiotypic vaccine might be able to enhance humoral and/or cellular immunity in NPC patients receiving radiotherapy.
    Chinese medical journal 05/2002; 115(4):567-70. · 0.90 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: An anti-idiotypic monoclonal antibody 2A9 (Ab2) was prepared, which mimicked the nasopharynegeal carcinoma (NPC) cell antigen defined by anti-NPC McAb Fcl. The abilities of 2A9’s inducing humoral and cellular immunity against NPC cell antigen were studied in syngeneic mice by inducing anti-Ab2 sera (Ab3) and delayed-type hypersensitivity. Two periods of phase 1 clinical trials were carried out, stage IV NPC patients receiving radiotherapy were chosen. Human anti-mouse antibodies (HAMA), anti-anti-idiotypic antibodies (Ab3), and anti-NPC cell antibodies (Abl′) were detected by ELISA. TNF-α,IL-2, IFN-γ levels in sera were determined by ELISA Kits. IL-2 mRNA expression in peripheral blood mononuclear cells (PBMC) were shown byin situ hybridization. The results showed that 2A9 was safe in applying on NPC patients and induced some humoral and/or cellular immune responses.
    Chinese Journal of Cancer Research 01/1997; 9(2):127-132. · 0.45 Impact Factor

Publication Stats

6 Citations
5.50 Total Impact Points

Institutions

  • 2005
    • Cancer Research Institute
      New York City, New York, United States
  • 2002–2003
    • Central South University
      • Cancer Research Institute
      Changsha, Hunan, China
  • 1997
    • Changsha Medical University
      Ch’ang-sha-shih, Hunan, China